New schizophrenia drug passes long-term safety check
NCT ID NCT04115319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called SEP-363856 to see if it is safe to take for a long time by people with schizophrenia. 305 adults aged 18 to 65 took part for about 57 weeks. The main goal was to track any side effects or serious health problems that happened while on the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Cerritos, California, 90703, United States
-
Research Site
Oakland, California, 94607, United States
-
Research Site
Oceanside, California, 92056, United States
-
Research Site
San Diego, California, 92103, United States
-
Research Site
Torrance, California, 90502, United States
-
Research Site
Miami, Florida, 33122, United States
-
Research Site
Miami Lakes, Florida, 33016, United States
-
Research Site
Atlanta, Georgia, 30328, United States
-
Research Site
Hoffman Estates, Illinois, 60169, United States
-
Research Site
Lincolnwood, Illinois, 60712, United States
-
Research Site
Shreveport, Louisiana, 71101, United States
-
Research Site
St Louis, Missouri, 63128, United States
-
Research Site
Las Vegas, Nevada, 89102, United States
-
Research Site
Cedarhurst, New York, 11516, United States
-
Research Site
Jamaica, New York, 11432, United States
-
Research Site
Rochester, New York, 14618, United States
-
Research Site
Charlotte, North Carolina, 28211, United States
-
Research Site
North Canton, Ohio, 44720, United States
-
Research Site
Brasov, 500079, Romania
-
Research Site
Bucharest, 041914, Romania
-
Research Site
Bucharest, 060222, Romania
-
Research Site
Bucharest, 41914,, Romania
-
Research Site
Iași, 700282, Romania
-
Research Site
Arkhangelsk, 163530, Russia
-
Research Site
Moscow, 127083, Russia
-
Research Site
Omsk, 644070, Russia
-
Research Site
Saint Petersburg, 188357, Russia
-
Research Site
Saint Petersburg, 190121, Russia
-
Research Site
Saint Petersburg, 192019, Russia
-
Research Site
Saint Petersburg, 195176, Russia
-
Research Site
Saint Petersburg, 199106, Russia
-
Research Site
Smolensk, 214031, Russia
-
Research Site
Stavropol, 357034, Russia
-
Research Site
Tomsk, 634014, Russia
-
Research Site
Yaroslavl, 150003, Russia
-
Research Site
Yekaterinburg, 620030, Russia
-
Research Site
Ivano-Frankivsk, 76011, Ukraine
-
Research Site
Kharkiv, 61068, Ukraine
-
Research Site
Kyiv, 03049, Ukraine
-
Research Site
Smila, 20708, Ukraine
-
Research Site
Ternopil, 46027, Ukraine
-
Research Site
Uzhhorod, 88000, Ukraine
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?